Try the Demo today!
| SEC Filing | Insider | Company | Trade Date | Transaction | Shares | Avg. Price | Total | % Holdings | Return |
|---|---|---|---|---|---|---|---|---|---|
| 08-Sep-23 4:00 PM View:  | Goater Jeff Director | Surface Oncology, Inc. (SURF) | 08-Sep-23 | Disposition | 129,222 | -- | -- | (100%) 129.22K to 0 | |
| 08-Sep-23 4:00 PM View: | Rath Henry C. Chief Business Officer | Surface Oncology, Inc. (SURF) | 08-Sep-23 | Disposition | 44,971 | -- | -- | (100%) 44.97K to 0 | |
| 08-Sep-23 4:00 PM View: | Palombella Vito J. Chief Scientific Officer | Surface Oncology, Inc. (SURF) | 08-Sep-23 | Disposition | 87,212 | -- | -- | (100%) 87.21K to 0 | |
| 08-Sep-23 4:00 PM View: | Adams Chandra Deputy GC | Surface Oncology, Inc. (SURF) | 08-Sep-23 | Disposition | 23,884 | -- | -- | (100%) 23.88K to 0 | |
| 08-Sep-23 4:00 PM View: | Oneill Alison CHIEF MEDICAL OFFICER | Surface Oncology, Inc. (SURF) | 08-Sep-23 | Disposition | 56,686 | -- | -- | (100%) 56.69K to 0 | |
| 08-Sep-23 4:00 PM View: | Grayzel David S. Director | Surface Oncology, Inc. (SURF) | 08-Sep-23 | Disposition | 2,945,450 | -- | -- | (100%) 2.95M to 0 | |
| 08-Sep-23 4:00 PM View: | Fees Jessica Chief Financial Officer | Surface Oncology, Inc. (SURF) | 08-Sep-23 | Disposition | 101,915 | -- | -- | (100%) 101.92K to 0 | |
| 08-Sep-23 4:00 PM View: | Sigal Charles Elliott Director | Surface Oncology, Inc. (SURF) | 08-Sep-23 | Disposition | 45,453 | -- | -- | (100%) 45.45K to 0 | |
| 08-Sep-23 4:00 PM View: | Ross Robert W. Chief Executive Officer Director | Surface Oncology, Inc. (SURF) | 08-Sep-23 | Disposition | 83,193 | -- | -- | (100%) 83.19K to 0 | |
| 11-Aug-23 8:00 PM View: | Ross Robert W. Chief Executive Officer | Surface Oncology, Inc. (SURF) | 01-Aug-23 | Sale | 16,713 | $0.94 | $15,710.20 | (17%) 99.91K to 83.19K | |
| 11-Aug-23 8:00 PM View: | Adams Chandra Deputy GC | Surface Oncology, Inc. (SURF) | 01-Aug-23 | Sale | 3,901 | $0.94 | $3,666.94 | (11%) 34.8K to 30.9K | |
| 11-Aug-23 8:00 PM View: | Oneill Alison CHIEF MEDICAL OFFICER | Surface Oncology, Inc. (SURF) | 01-Aug-23 | Sale | 7,042 | $0.94 | $6,619.48 | (11%) 63.73K to 56.69K | |
| 11-Aug-23 8:00 PM View: | Fees Jessica Chief Financial Officer | Surface Oncology, Inc. (SURF) | 01-Aug-23 | Sale | 9,434 | $0.94 | $8,867.96 | (8%) 111.35K to 101.92K | |
| 05-Aug-22 8:01 PM View: | Oneill Alison CHIEF MEDICAL OFFICER | Surface Oncology, Inc. (SURF) | 03-Aug-22 | Sale | 4,463 | $1.72 | $7,676.36 | (7%) 68.19K to 63.73K | |
| 05-Aug-22 8:00 PM View: | Fees Jessica Chief Financial Officer | Surface Oncology, Inc. (SURF) | 03-Aug-22 | Sale | 5,980 | $1.72 | $10,285.60 | (5%) 117.33K to 111.35K | |
| 05-Aug-22 8:01 PM View: | Rath Henry C. Chief Business Officer | Surface Oncology, Inc. (SURF) | 03-Aug-22 | Sale | 5,676 | $1.72 | $9,762.72 | (15%) 38.0K to 32.32K | |
| 05-Aug-22 8:00 PM View: | Palombella Vito J. Chief Scientific Officer | Surface Oncology, Inc. (SURF) | 03-Aug-22 | Sale | 4,463 | $1.72 | $7,676.36 | (5%) 91.67K to 87.21K | |
| 05-Aug-22 8:00 PM View: | Ross Robert W. Chief Executive Officer | Surface Oncology, Inc. (SURF) | 03-Aug-22 | Sale | 10,594 | $1.72 | $18,221.70 | (10%) 110.5K to 99.91K | |
| 03-Mar-22 8:00 PM View: | Palombella Vito J. Chief Scientific Officer | Surface Oncology, Inc. (SURF) | 01-Mar-22 | Grant | 38,000 | -- | -- | 71% 53.67K to 91.67K | |
| 03-Mar-22 8:00 PM View: | Ross Robert W. Chief Executive Officer | Surface Oncology, Inc. (SURF) | 01-Mar-22 | Grant | 56,000 | -- | -- | 103% 54.5K to 110.5K | |
| 03-Mar-22 8:00 PM View: | Rath Henry C. Chief Business Officer | Surface Oncology, Inc. (SURF) | 01-Mar-22 | Grant | 38,000 | -- | -- | 100% 0 to 38.0K | |
| 03-Mar-22 8:00 PM View: | Oneill Alison CHIEF MEDICAL OFFICER | Surface Oncology, Inc. (SURF) | 01-Mar-22 | Grant | 38,000 | -- | -- | 126% 30.19K to 68.19K | |
| 03-Mar-22 8:00 PM View: | Fees Jessica Chief Financial Officer | Surface Oncology, Inc. (SURF) | 01-Mar-22 | Grant | 38,000 | -- | -- | 48% 79.33K to 117.33K | |
| 14-Jan-22 8:30 PM View: | Palombella Vito J. Chief Scientific Officer | Surface Oncology, Inc. (SURF) | 21-Jul-21 | Market Sale | 26,325 | $6.10 | $160,582.00 | (33%) 80.0K to 53.67K | 26% |
| 14-Jan-22 8:30 PM View: | Ross Robert W. Chief Executive Officer | Surface Oncology, Inc. (SURF) | 21-Jul-21 | Market Sale | 33,500 | $6.10 | $204,350.00 | (38%) 88.0K to 54.5K | 26% |
| 14-Jan-22 8:30 PM View: | Goater Jeff Director | Surface Oncology, Inc. (SURF) | 21-Jul-21 | Market Sale | 127,778 | $6.10 | $779,446.00 | (50%) 257.0K to 129.22K | 26% |
| 14-Jan-22 8:30 PM View: | Oneill Alison CHIEF MEDICAL OFFICER | Surface Oncology, Inc. (SURF) | 21-Jul-21 | Market Sale | 14,809 | $6.10 | $90,334.90 | (33%) 45.0K to 30.19K | |
| 14-Jan-22 8:30 PM View: | Fees Jessica Chief Financial Officer | Surface Oncology, Inc. (SURF) | 21-Jul-21 | Market Sale | 19,854 | $6.10 | $121,109.00 | (20%) 99.18K to 79.33K | 26% |
| 14-Jan-22 8:30 PM View: | Nogelo Liisa I Chief Legal Officer | Surface Oncology, Inc. (SURF) | 21-Jul-21 | Market Sale | 26,325 | $6.10 | $160,582.00 | (33%) 80.0K to 53.67K | 26% |
| 11-Jun-21 8:30 PM View: | Goater Jeff Director | Surface Oncology, Inc. (SURF) | 11-Jun-21 | Option Exercise | 10,273 | $4.14 | $42,530.20 | 4% 262.0K to 272.27K | |
| 11-Jun-21 8:30 PM View: | Goater Jeff Director | Surface Oncology, Inc. (SURF) | 11-Jun-21 | Market Sale | 5,000 | $7.61 | $38,049.50 | (2%) 262.0K to 257.0K | |
| 11-Jun-21 8:30 PM View: | Goater Jeff Director | Surface Oncology, Inc. (SURF) | 11-Jun-21 | Market Option Sale | 10,273 | $7.61 | $78,176.50 | (4%) 272.27K to 262.0K | |
| 11-Jun-21 8:30 PM View: | Goater Jeff Director | Surface Oncology, Inc. (SURF) | 10-Jun-21 | Market Option Sale | 234,727 | $7.66 | $1,798,620.00 | (47%) 496.73K to 262.0K | |
| 11-Jun-21 8:30 PM View: | Goater Jeff Director | Surface Oncology, Inc. (SURF) | 10-Jun-21 | Option Exercise | 234,727 | $4.14 | $971,770.00 | 90% 262.0K to 496.73K | |
| 18-Feb-21 8:00 PM View: | Ross Robert W. Chief Medical Officer | Surface Oncology, Inc. (SURF) | 16-Feb-21 | Market Sale (Planned) | 1,000 | $11.35 | $11,350.00 | (1%) 89.0K to 88.0K | 8% |
| 09-Feb-21 8:00 PM View: | Goater Jeff Chief Executive Officer Director | Surface Oncology, Inc. (SURF) | 08-Feb-21 | Market Option Sale (Planned) | 2,500 | $12.50 | $31,250.00 | (< 1%) 264.5K to 262.0K | |
| 09-Feb-21 8:00 PM View: | Fees Jessica See Remarks | Surface Oncology, Inc. (SURF) | 08-Feb-21 | Market Sale (Planned) | 1,500 | $12.45 | $18,675.00 | (1%) 100.68K to 99.18K | (< 1%) |
| 09-Feb-21 8:00 PM View: | Goater Jeff Chief Executive Officer Director | Surface Oncology, Inc. (SURF) | 08-Feb-21 | Option Exercise | 2,500 | $3.18 | $7,950.00 | < 1% 262.0K to 264.5K | |
| 03-Feb-21 8:00 PM View: | Goater Jeff Chief Executive Officer Director | Surface Oncology, Inc. (SURF) | 01-Feb-21 | Market Option Sale (Planned) | 2,500 | $10.69 | $26,717.50 | (< 1%) 264.5K to 262.0K | |
| 03-Feb-21 8:00 PM View: | Fees Jessica See Remarks | Surface Oncology, Inc. (SURF) | 01-Feb-21 | Market Sale (Planned) | 1,500 | $11.19 | $16,785.00 | (1%) 102.18K to 100.68K | 3% |
| 03-Feb-21 8:00 PM View: | Goater Jeff Chief Executive Officer Director | Surface Oncology, Inc. (SURF) | 01-Feb-21 | Option Exercise | 2,500 | $3.18 | $7,950.00 | < 1% 262.0K to 264.5K | |
| 21-Jan-21 8:17 PM View: | Goater Jeff Chief Executive Officer Director | Surface Oncology, Inc. (SURF) | 19-Jan-21 | Option Exercise | 5,000 | $3.18 | $15,900.00 | 2% 262.0K to 267.0K | |
| 21-Jan-21 8:17 PM View: | Goater Jeff Chief Executive Officer Director | Surface Oncology, Inc. (SURF) | 19-Jan-21 | Market Option Sale (Planned) | 5,000 | $13.00 | $65,000.00 | (2%) 267.0K to 262.0K | |
| 15-Jan-21 8:00 PM View: | Ross Robert W. Chief Medical Officer | Surface Oncology, Inc. (SURF) | 15-Jan-21 | Market Sale (Planned) | 2,000 | $12.25 | $24,500.00 | (2%) 91.0K to 89.0K | 2% |
| 15-Jan-21 8:00 PM View: | Ross Robert W. Chief Medical Officer | Surface Oncology, Inc. (SURF) | 14-Jan-21 | Market Sale (Planned) | 7,000 | $11.95 | $83,650.00 | (7%) 98.0K to 91.0K | 0% |
| 21-Dec-20 1:32 PM View: | Grayzel David S. Director | Surface Oncology, Inc. (SURF) | 17-Dec-20 | Private Sale Duplicate | 1,700,000 | $18.10 | $30,770,000.00 | (37%) 4.65M to 2.95M | |
| 21-Dec-20 1:32 PM View: | Atlas Venture Fund Ix, L.P. 10% Owner | Surface Oncology, Inc. (SURF) | 17-Dec-20 | Private Sale | 1,700,000 | $18.10 | $30,770,000.00 | (37%) 4.65M to 2.95M | |
| 17-Dec-20 8:00 PM View: | Ross Robert W. Chief Medical Officer | Surface Oncology, Inc. (SURF) | 15-Dec-20 | Market Sale (Planned) | 1,000 | $10.48 | $10,480.00 | (1%) 99.0K to 98.0K | 8% |
| 15-Dec-20 8:00 PM View: | Ross Robert W. Chief Medical Officer | Surface Oncology, Inc. (SURF) | 11-Dec-20 | Market Sale (Planned) | 1,405 | $10.05 | $14,120.20 | (1%) 100.41K to 99.0K | 4% |
| 27-Nov-20 8:00 PM View: | Fees Jessica See Remarks | Surface Oncology, Inc. (SURF) | 25-Nov-20 | Option Exercise | 1,383 | $5.06 | $6,996.44 | 1% 100.8K to 102.18K |
